TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients scheduled for primary unilateral total knee arthroplasty~2. Preoperative Hemoglobin \>11mg/dL~3. Preoperative platelet count of \>150,000~Exclusion Criteria:~1. Patients unable to take aspirin or apixaban for VTE prophylaxis~2. Allergy to any of the ingredients in bone wax (beeswax, paraffin, or isopropyl palmitate)~3. Patients taking clopidogrel (Plavix), ticagrelor (Brilinta), or prasugrel (Effient) or any other antiplatelet medication (except for aspirin 81 mg)~4. Patients unable to get IV Tranexamic Acid for any reason~5. Patients requiring anticoagulant treatment prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: ACTIVE_COMPARATOR): This arm will have bone wax applied to the exposed cancellous surfaces of the bone.
- Control Arm (Type: NO_INTERVENTION): This arm will serve as the control group. Bone wax will not be used in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gastric Emptying Following an Oral Carbohydrate Load in Women Admitted for Elective Cesarean Delivery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* non-laboring pregnant women ≥36 weeks gestational age, scheduled for cesarean delivery~* ≥18 years of age~* ASA physical status II to III~* weight 50 to 120 kg~* height ≥150 cm~* ability to understand the rationale of the study assessments.~Exclusion Criteria:~* Diabetes Mellitus~* patients who have not complied with fasting guidelines (8 hours of solid food or thick fluids, and no clear fluid 3 hours before the scheduled arrival time on Labor and Delivery for the study)~* abnormal anatomy of the upper gastrointestinal tract, and previous surgical procedures on the esophagus, stomach, or upper abdomen~* gastric ultrasound that is not compatible with empty stomach (gastric antrum grade 0 or 1 and CSA \< 10.3 cm2 in the right lateral decubitus).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 400ml cranberry juice (Type: EXPERIMENTAL): Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with symptoms suggestive for ACS presenting within 48 hours after onset in the ER/ Chest Pain Unit (CPU)~* Patient has at least one elevated high-sensitivity troponin I or T value~* Chest pain is classified as non-ACS, despite elevated hsTn (e.g. because of missing troponin dynamics)~* At least 50 years of age~Exclusion Criteria:~* Indication for antiplatelet therapy (e.g transient ischemic attack, or stable coronary artery diseases -CAD) or anticoagulation therapy (such as atrial fibrillation)~* Indication for anti-lipid therapy~* Any evidence of an acute myocardial necrosis (e.g imaging evidence of new regional wall motion abnormality, or significant ST-segment-T wave (ST-T) changes in ECG)~* Untreated clinically significant CAD requiring revascularization~* Hemoglobin value below 8 mg/d, and/or creatinine kinase ≥3 times ULN, and/or AST or ALT ≥3 times ULN~* Active malignancy of any organ system, treated or untreated. Subjects have to be in remission for at least 36 months to be eligible.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin 100 mg once daily and Placebo Atorvastatin once daily
- Atorvastatin (Type: ACTIVE_COMPARATOR): Atorvastatin 20 mg once daily and Placebo Aspirin once daily
- Aspirin-Atorvastatin (Type: EXPERIMENTAL): Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Aspirin once daily and Placebo Atorvastatin once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study for the BONGO NASAL Expiratory Positive Airway Pressure (EPAP) Device in the Treatment of Obstructive Sleep Apnea (OSA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Capacity and willingness to sign informed consent~* ≥ 21 years of age~* Diagnosis of mild to moderate OSA (AHI ≥ 5 and AHI \< 30) within 12 months of the screening visit.~* Able to tolerate using the device during a day time trial/acclimation~* Are currently using CPAP or have been prescribed CPAP and are considered CPAP non-adherent (as per either their CPAP data card and/or verbal confirmation of a diagnosis and unwillingness to use CPAP)~Exclusion Criteria:~* Nasal deformities~* Severe nasal allergies~* Rhinitis or moderate nasal congestion, acute upper respiratory (including nasal, sinus or middle ear) inflammation or infection, or perforation of the ear drum~* Co-morbid sleep disorders~* Currently on a hypnotic for insomnia (who have had insomnia for more than a month and take a hypnotic on a daily basis and/or transient insomnia being treated)~* Uncontrolled or serious illness, including but not limited to: severe breathing disorders including hypercapnic respiratory failure, respiratory muscle weakness, bullous lung disease (as seen in some types of emphysema), bypassed upper airway, pneumothorax, pneumomediastinum, etc.; severe heart disease (including heart failure); or pathologically low blood pressure.~* Full Face Mask user~* Mouth breather~* Pregnant (Female subjects of child bearing age will be asked if they are and/or planning on becoming pregnant during the study; acceptable methods of birth control include birth control pills and barrier method)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment~* Baseline NIHSS \> 5~Exclusion Criteria:~* No intracranial, extravascular blood on CT~* Hypertension (systolic \> 185; diastolic \> 105)~* Baseline fibrinogen level \< 100 mg/dL~* Thrombocytopenia (\< 100,000 / mm3)~* Recent (\< 3 days) or anticipated (\< 5 days) use of a thrombolytic agent~* Recent (\< 14 days) or anticipated surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous ancrod (Type: EXPERIMENTAL): Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
- Intravenous Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Disk of Amniotic Membrane (Visio-AMTRIX) in Postoperative Care After PKR

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18 to 80 years.~* Patient undergoing bilateral PRK procedure for myopia, astigmatism or hypermetropia with technique chosen for one of the following reasons: thin cornea, irregular cornea, suspected keratoconus, practice of combat or contact sports, professional activity at risk of direct impact.~* Patient understanding french language.~* Patient who received the study information and provided written consent to participation in the study.~* Patient who is a member or a beneficiary of a national health insurance plan.~Exclusion Criteria:~* Pregnant woman.~* Patient with a contraindication to PRK.~* Diabetic patient.~* Patient allergic to Oxybuprocaine and / or Tetracaine eye drops, to local anesthetics or to fluorescein.~* Monophthalmic patient.~* Person deprived of liberty by a judicial or administrative decision.~* Adult subjected to a legal protection measure or unable to express his / her consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Therapeutic lens alone (Type: ACTIVE_COMPARATOR): None
- Therapeutic lens + amniotic membrane (Visio-AMTRIX) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Preliminary Efficacy Study of V404 PDS in Uveitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Confirmed diagnosis of active uveitis~* Sufficient lens/media clarity~* Meet best-corrected visual acuity criteria~* Willing and able to use contraception~Exclusion Criteria:~* Pregnant, breast feeding~* Uncontrolled glaucoma~* Intraocular surgery or periocular/intraocular injections within 6 weeks~* Periocular or intraocular steroid within 3 months~* Prior vitrectomy~* Prior corneal transplant~* Prior fluocinolone implant~* Allergy or sensitivity to study drug~* Participation in other trial within 30 days~* Abnormal liver function~* History of positive serum tuberculosis test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose V404 PDS (Type: EXPERIMENTAL): Sustained intravitreal delivery of methotrexate (0.6 mg)
- High Dose V404 PDS (Type: EXPERIMENTAL): Sustained intravitreal delivery of methotrexate (2.3 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Determination of Upper Airway Collapsibility During Routine CPAP Titration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of OSA and stable on CPAP treatment \> 3 months~Exclusion Criteria:~* Pregnancy~* Currently smoking~* Any respiratory disorder other than OSA or well controlled asthma~* Medications known to affect respiratory function (e.g. opioids, benzodiazepines, etc)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Obstructive Sleep Apnea (Type: EXPERIMENTAL): Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) \> 3 months to verify the Pcrit measurement obtained by the clinical equipment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal status~* Currently being treated with an AI in the adjuvant setting (minimum for 8 weeks)~* AIMSS as determined by new or worsened musculoskeletal complaints following AI therapy~* Vitamin D deficiency (\<30ng/ml)~* Caucasian~Exclusion Criteria:~* Hormone replacement therapy last 6 months~* Current use or in the last 12 months of bisphosphonates~* Tamoxifen use in last 6 months~* History of kidney stones~* History of hypercalcemia/hypercalciuria or hyperthyroidism~* Paget's disease of the bone~* Current use of Digitalis/digoxin or thiazide diuretics~* Current use of vitamin D (or multivitamin) supplementation should be stopped

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin D3 (Type: EXPERIMENTAL): 1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
- Placebo (Type: PLACEBO_COMPARATOR): 1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Timing for Removal of Chest Tubes in Adult Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All consecutive patients undergoing elective open heart surgery in full or lower hemisternotomy with or without cardiopulmonary bypass including coronary artery bypass grafting, valve surgery, simple aortic surgery or combinations.~Exclusion Criteria:~Cardiac procedures deemed not eligible to chest tube removal on the day of surgery due to increased bleeding risk due to:~* Procedures in hypothermic circulatory arrest~* Previous cardiac surgery~* Procedures performed through upper hemisternotomy~* Emergent treatment required (\< 24 hours)~* Non-aspirin antiplatelet drugs stopped \< 5 days preoperatively (Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine)~* Current use of vitamin K antagonists or new oral non-vitamin K anticoagulants~* Platelet count \> 450 or \<100 x 109/l prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Day O chest tube removal (Type: ACTIVE_COMPARATOR): Chest tubes maybe removed ten hours after arrival at the intensive care provided standardized removal criteria are fulfilled:~1. blood loss through chest tubes less than 200 ml during the last four hours~2. no air leak~3. the patient extubated and mobilized It remains at the discretion of the attending cardiac surgeon to postpone chest tube removal in cases of increased bleeding risk, due to circumstances which develop during the perioperative period
- Day 1 chest tube removal (Type: ACTIVE_COMPARATOR): Chest tubes are removed in the early morning of the first postoperative day, provided standardized removal criteria are fulfilled:~1. blood loss through chest tubes less than 200 ml during the last four hours~2. no air leak~3. the patient extubated and mobilized It remains at the discretion of both the attending surgeon and anestesiologist to remove chest tubes prematurely in cases of drain-induced, severe analgetic resistant, intractable pain resistant to analgetic treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults; 18 and over~* At least 10 and no more than 30 clinically typical actinic keratoses on the face~Exclusion Criteria:~* Hypertrophic actinic keratoses or other skin lesions on the head that might required excluded treatment during the study~* Known contraindication to treatment with imiquimod or photodynamic therapy~* Condition that would limit compliance, be a potential safety risk, or require therapy with an excluded treatment~* Systemically immunocompromised~* Pregnant or nursing~* Dermatologic disease and/or condition in treatment area that might exacerbated by treatment with imiquimod, cause difficulty with examination, or require therapy with an excluded treatment~* Participation in another clinical study~* Treatment within the past 60 days with:~  * Ultraviolet therapy~ * Systemic immunomodulators~ * Chemotherapeutic or cytotoxic agents~ * Investigational agents~* Treatment on the head within the past 60 days with:~  * Imiquimod~ * Photodynamic therapy~ * Red or blue light source therapy~ * Cryotherapy or chemotherapy~ * Surgical excision or curettage~ * Topical corticosteroids~ * Laser~ * Dermabrasion~ * Chemical peel~ * Topical retinoids~ * Topical 5-fluorouracil~ * Topical pimecrolimus or tacrolimus~ * Topical diclofenac~* Treatment for actinic keratoses on the head within the past 60 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Imiquimod & photodynamic therapy (Type: EXPERIMENTAL): Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
- Imiquimod (Type: ACTIVE_COMPARATOR): Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Healthy, elderly, non-smoking men and post-menopausal women~* Ability to give informed consent~Main Exclusion Criteria:~* Current or history of uncontrolled hypertension, major depression, Parkinson's disease, stroke and diabetes.~* Physical or behavioral conditions that may alter brain function

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- HT-0712 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be at least 18 years of age.~2. Subject has a Stage II-IV pressure ulcer located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.~3. Pressure ulcer should be present for 4 weeks duration and have a ulcer surface area \> 2cm2~4. If multiple ulcers are present, one ulcer must be identified as the index ulcer.~5. The index ulcer is free from active infection at the time of randomization.~6. Willingness to off-load or pressure redistribute ulcer for duration of enrollment~7. The index ulcer has been offloaded for at least 7 days prior to randomization.~8. The index ulcer must have been present for at least 30 days at time of study enrollment.~9. The index ulcer is separated at least 4 cm from all other ulcers at Study Day -7 and Study Day 0 (post-debridement) and has a margin of intact skin sufficient for anchoring of the required study dressing.~10. Subject has read and signed the IRB/IEC approved Informed Consent Form (ICF) before screening procedures are undertaken.~Exclusion Criteria:~1. Presence of signs and symptoms of infection at the index ulcer site, including but not limited to cellulitis, acute osteomyelitis, excessive exudate, gangrene or deep tissue infection~2. The index ulcer is not free of necrotic tissue and is unable to tolerate debridement~3. Non-enteric or unexplored sinus tract~4. Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study~5. Subject has a known sensitivity to porcine materials~6. Subject has a known sensitivity to polyhexamethylenebiguanide (PHMB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PuraPly® AM plus Standard of Care (Type: ACTIVE_COMPARATOR): None
- Standard of Care (SOC) for Pressure Ulcers (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues